3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
151
Lung Neoplasms
34
Carcinoma
11
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Neoplasms
9
Neoplasm Metastasis
9
Mesothelioma
5
Adenocarcinoma of Lung
5
Uterine Cervical Neoplasms
4
Thoracic Neoplasms
4
Respiratory Tract Neoplasms
4
Respiratory Tract Diseases
4
Mesothelioma, Malignant
4
Lung Diseases
4
Carcinoma, Bronchogenic
4
Non-squamous Non-small Cell Lung Cancer
3
Non-Squamous Non-Small Cell Lung Cancer
3
Neoplasms by Site
3
NSCLC
3
Bronchial Neoplasms
3
Adenocarcinoma
3
Recurrence
2
Non-Squamous Non-small Cell Lung Cancer
2
Non Small Cell Lung Carcinoma NSCLC
2
Head and Neck Neoplasms
2
Brain Neoplasms
2
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Interventions
pembrolizumab
2
Zoledronic Acid
1
Pemetrexed
1
Denosumab
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplastic Processes
×
Pemetrexed
×
Clear all
NCT06119581
2026-05-19
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled